Using VeraTagTM technology, we have developed multiple quantitative and sensitive assays for measurements of activated receptor species in the HER1-HER2 signaling axis in both breast tumor cell lysates and FFPE cell and tumor formats. This evidence concerns the gene EGFR and breast neoplasm.